Transplant-associated thrombotic microangiopathy in pediatric patients treated with sirolimus and tacrolimus

Pediatric Blood and Cancer

Volumn 57, Issue 1, 2011, Pages 142-146

  Rosenthal, Joseph ^a   Pawlowska, Anna ^a   Bolotin, Ellen ^a   Cervantes, Cheryl ^a   Maroongroge, Sean ^a   Thomas, Sandra H ^a   Forman, Stephen J ^a  

^a City of Hope ^*  (United States)

Author keywords

Calcineurin inhibitor; Sirolimus; Tacrolimus; Thrombotic microangiopathy; TMA

Indexed keywords

RAPAMYCIN; TACROLIMUS;

ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; LABORATORY TEST; MALE; ORGAN INJURY; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; RETROSPECTIVE STUDIES; SIROLIMUS; TACROLIMUS; THROMBOTIC MICROANGIOPATHIES; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 79955706430     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22861     Document Type: Article

References (23)

1. Ho VT, Cutler C, Carter S, et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005;11:571-575.
2. George JN, Li X, McMinn JR, et al. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma. Transfusion 2004;44:294-304.
3. Young BA, Marsh CL, Alpers CE, et al. Cyclosporine-associated thrombotic microangiopathy/hemolytic uremic syndrome following kidney and kidney-pancreas transplantation. Am J Kidney Dis 1996;28:561-571.
4. Franco A, Hernandez D, Capdevilla L, et al. De novo hemolytic-uremic syndrome/thrombotic microangiopathy in renal transplant patients receiving calcineurin inhibitors: role of sirolimus. Transplant Proc 2003;35:1764-1766.
5. Sarkodee-Adoo C, Sotirescu D, Sensenbrenner L, et al. Thrombotic microangiopathy in blood and marrow transplant patients receiving tacrolimus or cyclosporine A. Transfusion 2003;43:78-84.
6. Abraham KA, Little MA, Dorman AM, et al. Hemolytic-uremic syndrome in association with both cyclosporine and tacrolimus. Transpl Int 2000;13:443-447.
7. Groth CG, Backman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999;67:1036-1042.
8. Longoria J, Roberts RF, Marboe CC, et al. Sirolimus (rapamycin) potentiates cyclosporine in prevention of acute lung rejection. J Thorac Cardiovasc Surg 1999;117:714-718.
9. Rodriguez R, Nakamura R, Palmer JM, et al. A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens. Blood 2010;115:1098-1105.
10. Barone GW, Gurley BJ, Abul-Ezz SR, et al. Sirolimus-induced thrombotic microangiopathy in a renal transplant recipient. Am J Kidney Dis 2003;42:202-206.
11. Langer RM, Van Buren CT, Katz SM, et al. De novo hemolytic uremic syndrome after kidney transplantation in patients treated with cyclosporine-sirolimus combination. Transplantation 2002;73:756-760.
12. Paramesh AS, Grosskreutz C, Florman SS, et al. Thrombotic microangiopathy associated with combined sirolimus and tacrolimus immunosuppression after intestinal transplantation. Transplantation 2004;77:129-131.
13. Robson M, Cote I, Abbs I, et al. Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage? Am J Transplant 2003;3:324-327.
14. Cutler C, Henry NL, Magee C, et al. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005;11:551-557.
15. Pham PT, Peng A, Wilkinson AH, et al. Cyclosporine and tacrolimus-associated thrombotic microangiopathy. Am J Kidney Dis 2000;36:844-850.
16. Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int 2001;60:831-846.
17. Mitra D, Jaffe EA, Weksler B et al. Thrombotic thrombocytopenic purpura and sporadic hemolytic-uremic syndrome plasmas induce apoptosis in restricted lineages of human microvascular endothelial cells. Blood 1997;89:1224-1234.
18. Shulman H, Striker G, Deeg HJ, et al. Nephrotoxicity of cyclosporin A after allogeneic marrow transplantation: glomerular thromboses and tubular injury. N Engl J Med 1981;305:1392-1395.
19. Atkinson K, Biggs JC, Hayes J, et al. Cyclosporin a associated nephrotoxicity in the first 100 days after allogeneic bone marrow transplantation: three distinct syndromes. Br J Haematol 1983;54:59-67.
20. Bonser RS, Adu D, Franklin I, et al. Cyclosporin-induced haemolytic uraemic syndrome in liver allograft recipient. Lancet 1984;2:1337.
21. Van Buren D, Van Buren CT, Flechner SM et al. De novo hemolytic uremic syndrome in renal transplant recipients immunosuppressed with cyclosporine. Surgery 1985;98:54-5462.
22. Cutler C, Kim HT, Hochberg E, et al. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2004;10:328-336.
23. Antin JH, Kim HT, Cutler C, et al. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood 2003;102:1601-1605.